Abdominal or Transanal TME in Therapy of Rectal Cancer: A Retrospective Cohort Study
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 300
- 试验地点
- 2
- 主要终点
- disease-specific survival
研究概览
简要总结
This study assessed whether transanal TME in patients with rectal cancer is superior to open, laparoscopic, and robotic TME (abdominal TME (abTME)) regarding oncological outcome, postoperative morbidity and 90-day mortality.
详细描述
Rectal cancer accounts for 3.8% of all new cancer diagnosis and for 3.4% of all cancer-related deaths in the world in 2020. Regarding treatment of rectal cancer, it is essential to perform surgery along the anatomical and embryological planes. This technique called total mesorectal excision (TME) reduces the local recurrence rate and improves the survival. Since the early 2000, TME has changed from open to laparoscopic approach due to better results in short-term outcome. Nevertheless, oncological benefits are modest. In 2009 the first ever transanal TME (taTME) war performed. This novel technique combines abdominal with transanal dissection. Because the distal part of the rectum is approached from below, a better visualization of the mesorectal plane resulting in higher rate of free CRM and of complete TME specimen grade (Quirke Score) can be accomplished. However, taTME remains a hot topic in the current scientific literature. In Norway and the Netherlands a higher rate of anastomotic leakage as well as a higher rate of local recurrence (9.5%) with multifocal growth pattern were described.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •all patients receiving elective total mesorectal excision
排除标准
- •diagnosis other than rectal cancer
- •partial mesorectal excision
- •discontinuity resection (no anastomosis)
- •incomplete Staging
- •metastatic cancer
- •lack of follow-up
- •decline of a retrospective data Analysis
- •age under 18 years
结局指标
主要结局
disease-specific survival
时间窗: 60 months
time from surgery to end of follow-up or death due to or recurrence of rectal cancer
Overall survival
时间窗: 60 months
time from surgery to end of follow-up or death
cancer-specific survival
时间窗: 60 months
time from surgery to end of follow-up or death due to rectal cancer
次要结局
- positive resection margin(30 days)
- relapse-free survival(60 months)
- number of lymph nodes(30 days)
- postoperative 90-day mortality(90 days)
- recurrence-free survival(60 months)
- postoperative morbidity(30 days)
- Quirke Score(30 days)
- circular resection margin (CRM)(30 days)
研究者
Lukas Marti
Dr. med. Lukas Marti, Leitender Arzt Chirurgie
Cantonal Hospital of St. Gallen
